<?xml version='1.0' encoding='utf-8'?>
<document id="20942779"><sentence text="Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability."><entity charOffset="62-73" id="DDI-PubMed.20942779.s1.e0" text="clopidogrel" /><entity charOffset="78-87" id="DDI-PubMed.20942779.s1.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s1.e0" e2="DDI-PubMed.20942779.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s1.e0" e2="DDI-PubMed.20942779.s1.e1" /></sentence><sentence text="Thienopyridine antiaggregating platelet agents (clopidogrel and prasugrel) act as irreversible P2Y12 receptor inhibitors"><entity charOffset="0-14" id="DDI-PubMed.20942779.s2.e0" text="Thienopyridine" /><entity charOffset="48-59" id="DDI-PubMed.20942779.s2.e1" text="clopidogrel" /><entity charOffset="64-73" id="DDI-PubMed.20942779.s2.e2" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s2.e0" e2="DDI-PubMed.20942779.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s2.e0" e2="DDI-PubMed.20942779.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20942779.s2.e0" e2="DDI-PubMed.20942779.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20942779.s2.e1" e2="DDI-PubMed.20942779.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20942779.s2.e1" e2="DDI-PubMed.20942779.s2.e2" /></sentence><sentence text=" They are used with aspirin to prevent thrombotic complications after an acute coronary syndrome or percutaneous coronary intervention"><entity charOffset="20-27" id="DDI-PubMed.20942779.s3.e0" text="aspirin" /></sentence><sentence text=" A large interindividual variability in response to clopidogrel and to a lesser extent to prasugrel is observed and may be related to their metabolism"><entity charOffset="52-63" id="DDI-PubMed.20942779.s4.e0" text="clopidogrel" /><entity charOffset="90-99" id="DDI-PubMed.20942779.s4.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s4.e0" e2="DDI-PubMed.20942779.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s4.e0" e2="DDI-PubMed.20942779.s4.e1" /></sentence><sentence text=" Clopidogrel and prasugrel are indeed prodrugs converted into their respective active metabolites by several cytochromes P450 (CYPs)"><entity charOffset="1-12" id="DDI-PubMed.20942779.s5.e0" text="Clopidogrel" /><entity charOffset="17-26" id="DDI-PubMed.20942779.s5.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s5.e0" e2="DDI-PubMed.20942779.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s5.e0" e2="DDI-PubMed.20942779.s5.e1" /></sentence><sentence text=" Besides clopidogrel inactivation (85%) by esterases to the carboxylic acid, clopidogrel is metabolized by CYPs to 2-oxo-clopidogrel (15%) and further metabolized to an unstable but potent platelet-aggregating inhibitor"><entity charOffset="9-20" id="DDI-PubMed.20942779.s6.e0" text="clopidogrel" /><entity charOffset="60-75" id="DDI-PubMed.20942779.s6.e1" text="carboxylic acid" /><entity charOffset="77-88" id="DDI-PubMed.20942779.s6.e2" text="clopidogrel" /><entity charOffset="115-132" id="DDI-PubMed.20942779.s6.e3" text="2-oxo-clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e0" e2="DDI-PubMed.20942779.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e0" e2="DDI-PubMed.20942779.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e0" e2="DDI-PubMed.20942779.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e0" e2="DDI-PubMed.20942779.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e1" e2="DDI-PubMed.20942779.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e1" e2="DDI-PubMed.20942779.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e1" e2="DDI-PubMed.20942779.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e2" e2="DDI-PubMed.20942779.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20942779.s6.e2" e2="DDI-PubMed.20942779.s6.e3" /></sentence><sentence text=" Prasugrel is more potent than clopidogrel with a better bioavailability and lower pharmacodynamic variability"><entity charOffset="1-10" id="DDI-PubMed.20942779.s7.e0" text="Prasugrel" /><entity charOffset="31-42" id="DDI-PubMed.20942779.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s7.e0" e2="DDI-PubMed.20942779.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s7.e0" e2="DDI-PubMed.20942779.s7.e1" /></sentence><sentence text=" Prasugrel is completely converted by esterases to an intermediate oxo-metabolite (R-95913) further bioactivated by CYPs"><entity charOffset="1-10" id="DDI-PubMed.20942779.s8.e0" text="Prasugrel" /><entity charOffset="67-70" id="DDI-PubMed.20942779.s8.e1" text="oxo" /><pair ddi="false" e1="DDI-PubMed.20942779.s8.e0" e2="DDI-PubMed.20942779.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s8.e0" e2="DDI-PubMed.20942779.s8.e1" /></sentence><sentence text=" Numerous clinical studies have shown the influence of CYP2C19 polymorphism on clopidogrel antiplatelet activity"><entity charOffset="79-90" id="DDI-PubMed.20942779.s9.e0" text="clopidogrel" /></sentence><sentence text=" Moreover, unwanted drug-drug pharmacokinetic interactions influencing CYP2C19 activity and clopidogrel bioactivation such as with proton pump inhibitors remain a matter of intense controversy"><entity charOffset="92-103" id="DDI-PubMed.20942779.s10.e0" text="clopidogrel" /></sentence><sentence text=" Several studies have also demonstrated that CYP3A4/5 and CYP1A2 are important in clopidogrel bioactivation and should also be considered as potential targets for unwanted drug-drug interactions"><entity charOffset="82-93" id="DDI-PubMed.20942779.s11.e0" text="clopidogrel" /></sentence><sentence text=" Prasugrel bioactivation is mainly related to CYP3A4 and 2B6 activity and therefore the question of the effect of drug-drug interaction on its activity is open"><entity charOffset="1-10" id="DDI-PubMed.20942779.s12.e0" text="Prasugrel" /></sentence><sentence text=" The purpose of this review is to critically examine the current literature evaluating the influence of genetic and environmental factors such as unwanted drug-drug interaction affecting clopidogrel and prasugrel antiplatelet activity"><entity charOffset="187-198" id="DDI-PubMed.20942779.s13.e0" text="clopidogrel" /><entity charOffset="203-212" id="DDI-PubMed.20942779.s13.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.20942779.s13.e0" e2="DDI-PubMed.20942779.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20942779.s13.e0" e2="DDI-PubMed.20942779.s13.e1" /></sentence><sentence text="" /></document>